During the past decade, CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 8 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 6 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia" #1 sponsor was "Janssen Research & Development, LLC" with 8 trials, followed by "EMD Serono Research & Development Institute, Inc." with 4 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator and "Actoverco" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Breast Cancer" (2 trials), "Paroxysmal Nocturnal Hemoglobinuria" (2 trials), "Urinary Bladder Neoplasms" (2 trials) and "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia" in a lesser frequency.

Most popular intervention types in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia" are "Drug" (25 trials), "Biological" (4 trials), "Other" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (5 trials), "Cisplatin" (4 trials), "Paclitaxel" (4 trials), "Avelumab" (3 trials) and "Capecitabine" (3 trials). Other intervention names were less common.

The vast majority of trials in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia" are 24 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia". undefined are not yet recruiting, 11 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".